Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Total Non-Current Liabilities: 2010-2025

Historic Total Non-Current Liabilities for Catalyst Pharmaceuticals (CPRX) over the last 9 years, with Sep 2025 value amounting to $131.2 million.

  • Catalyst Pharmaceuticals' Total Non-Current Liabilities rose 21.16% to $131.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.2 million, marking a year-over-year increase of 21.16%. This contributed to the annual value of $123.5 million for FY2024, which is 55.79% up from last year.
  • As of Q3 2025, Catalyst Pharmaceuticals' Total Non-Current Liabilities stood at $131.2 million, which was up 13.51% from $115.6 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Total Non-Current Liabilities registered a high of $131.2 million during Q3 2025, and its lowest value of $48.3 million during Q3 2022.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $95.3 million (2024), whereas its average is $93.4 million.
  • Data for Catalyst Pharmaceuticals' Total Non-Current Liabilities shows a peak YoY spiked of 77.26% (in 2024) over the last 5 years.
  • Over the past 4 years, Catalyst Pharmaceuticals' Total Non-Current Liabilities (Quarterly) stood at $61.1 million in 2022, then rose by 29.61% to $79.3 million in 2023, then surged by 55.79% to $123.5 million in 2024, then grew by 21.16% to $131.2 million in 2025.
  • Its Total Non-Current Liabilities was $131.2 million in Q3 2025, compared to $115.6 million in Q2 2025 and $114.3 million in Q1 2025.